Immunotherapy Trial May Be Feasible to Combat Pediatric Pediatric Brain and Spinal Cord Tumors

An innovative clinical trial led by Dr. Nicholas Vitanza, a neuro-oncologist at Seattle Children’s, shows promise that delivering cancer-fighting chimeric antigen receptor (CAR) T cells directly to the brain for children and young adults with recurrent or refractory brain and central nervous system (CNS) tumors may be feasible and tolerable.

Read more: https://pulse.seattlechildrens.org/research-shows-seattle-childrens-pioneering-immunotherapy-trial-may-be-feasible-to-combat-pediatric-brain-and-spinal-cord-tumors/